Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK1 | P51617 | 7/20 | 0.57 |
| ▸ | MAP3K19 | Q56UN5 | 1/20 | 0.54 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.47 |
| ▸ | RHOA | P61586 | 6/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | CDK14 | O94921 | 4/20 | 0.43 |
| ▸ | CCNY | Q8ND76 | 4/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27084621 | 0.92 | IRAK1 (0.48) | IRAK1MAP3K19IRAK4RHOAKDM4E | |
| SCHEMBL23860733 | 0.92 | IRAK1 (0.48) | IRAK1MAP3K19IRAK4RHOAKDM4E | |
| SCHEMBL30165298 | 0.92 | IRAK1 (0.48) | IRAK1MAP3K19IRAK4RHOAKDM4E | |
| SCHEMBL23860729 | 0.92 | IRAK1 (0.48) | IRAK1MAP3K19IRAK4RHOAKDM4E | |
| SCHEMBL30279687 | 0.92 | IRAK1 (0.48) | IRAK1MAP3K19IRAK4RHOAKDM4E | |
| SCHEMBL23860752 | 0.90 | IRAK1 (0.50) | IRAK1MAP3K19IRAK4RHOAKDM4E | |
| SCHEMBL23860712 | 0.90 | IRAK1 (0.50) | IRAK1MAP3K19IRAK4RHOAKDM4E | |
| SCHEMBL30165302 | 0.90 | IRAK1 (0.50) | IRAK1MAP3K19IRAK4RHOAKDM4E | |
| SCHEMBL30165321 | 0.90 | IRAK1 (0.50) | IRAK1MAP3K19IRAK4RHOAKDM4E | |
| SCHEMBL27084644 | 0.90 | IRAK1 (0.50) | IRAK1MAP3K19IRAK4RHOAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3544970-B1 | INHIBITORS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES AND USES THEREOF | DANA FARBER CANCER INST INC (US) | 2021-11-17 | — | — | EP | disclosed |
| US-10975055-B2 | Inhibitors of interleukin-1 receptor-associated kinases and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-04-13 | — | — | US | disclosed |
| US-20200299257-A9 | INHIBITORS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-09-24 | — | — | US | disclosed |
| US-20190276426-A1 | INHIBITORS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-09-12 | — | — | US | disclosed |
| WO-2018098367-A1 | INHIBITORS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200299257-A9 | INHIBITORS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES AND USES THEREOF | IRAK1, IRAK4, IRAK2 | IRAK1 1/4885MAP3K19 15/4885IRAK4 2/4885 |
| US-10975055-B2 | Inhibitors of interleukin-1 receptor-associated kinases and uses thereof | IRAK1, IRAK4, IRAK2 | IRAK1 1/4885MAP3K19 15/4885IRAK4 2/4885 |
| US-20190276426-A1 | INHIBITORS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES AND USES THEREOF | IRAK1, IRAK4, IRAK2 | IRAK1 1/4885MAP3K19 15/4885IRAK4 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.